A.R.T. Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

A.R.T. Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,840	Closed	-$613K	–	880
2019 Q4	$613K	Buy	25,840 +4,400	+21%	+$107K	0.03%	757
2019 Q3	$589K	Buy	+21,440	New	+$635K	0.03%	791
2018 Q2	–	Sell	-9,340	Closed	-$427K	–	1733
2018 Q1	$427K	Sell	9,340 -62,200	-87%	-$2.6M	0.02%	1018
2017 Q4	$2.85M	Buy	+71,540	New	+$2.83M	0.13%	246
2016 Q2	–	Sell	-38,693	Closed	-$590K	–	1622
2016 Q1	$590K	Buy	+38,693	New	+$505K	0.03%	793
2015 Q3	–	Sell	-118,799	Closed	-$2.02M	–	1574
2015 Q2	$2.02M	Buy	+118,799	New	+$1.69M	0.07%	441
2015 Q1	–	Sell	-46,013	Closed	-$381K	–	1671
2014 Q4	$381K	Sell	46,013 -124,342	-73%	-$1.04M	0.01%	1017
2014 Q3	$1.48M	Buy	170,355 +139,454	+451%	+$1.26M	0.07%	384
2014 Q2	$338K	Buy	+30,901	New	+$275K	0.02%	949

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's SUPN Position: Q1 2020 in Review

A.R.T. Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 25,840 shares — an estimated $613K sold.

A.R.T. Advisors first reported a position in SUPN in Q2 2014 and held it in 9 quarters. The position peaked at $2.85M in Q4 2017. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

A.R.T. Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 25,840 Supernus Pharmaceuticals shares in Q1 2020, an estimated $613K.
A.R.T. Advisors first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 9 quarters.
A.R.T. Advisors's Supernus Pharmaceuticals position peaked at $2.85M in Q4 2017.
208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.